Paying users zone. Data is covered by hidden.

We accept:

Visa Mastercard American Express Maestro Discover JCB PayPal Apple Pay Google Pay
Verified by Visa MasterCard SecureCode American Express SafeKey
Unlock
Microsoft Excel LibreOffice Calc

Allergan PLC (AGN)

Enterprise Value to EBITDA (EV/EBITDA)

Difficulty: Intermediate

Earnings before Interest, Tax, Depreciation and Amortization (EBITDA)

Allergan PLC, EBITDA calculation

USD $ in thousands

Microsoft Excel LibreOffice Calc
12 months ended Dec 31, 2018 Dec 31, 2017 Dec 31, 2016 Dec 31, 2015 Dec 31, 2014
Net income (loss) attributable to shareholders hidden hidden hidden hidden hidden
Add: Net income attributable to noncontrolling interest hidden hidden hidden hidden hidden
Less: Income (loss) from discontinued operations, net of tax hidden hidden hidden hidden hidden
Add: Income tax expense hidden hidden hidden hidden hidden
Earnings before tax (EBT) hidden hidden hidden hidden hidden
Add: Interest expense hidden hidden hidden hidden hidden
Earnings before interest and tax (EBIT) hidden hidden hidden hidden hidden
Add: Depreciation hidden hidden hidden hidden hidden
Add: Amortization hidden hidden hidden hidden hidden
Earnings before interest, tax, depreciation and amortization (EBITDA) hidden hidden hidden hidden hidden

Based on: 10-K (filing date: 2019-02-15), 10-K (filing date: 2018-02-16), 10-K (filing date: 2017-02-24), 10-K (filing date: 2016-02-26), 10-K (filing date: 2015-02-18).

Item Description The company
EBITDA To calculate EBITDA analysts start with net earnings. To that earnings number, interest, taxes, depreciation, and amortization are added. EBITDA as a pre-interest number is a flow to all providers of capital. Allergan PLC’s EBITDA declined from 2016 to 2017 but then slightly increased from 2017 to 2018.

Enterprise Value to EBITDA Ratio, Current

Allergan PLC, current EV/EBITDA calculation, comparison to benchmarks

Microsoft Excel LibreOffice Calc
Selected Financial Data (USD $ in thousands)
Enterprise value (EV) hidden
Earnings before interest, tax, depreciation and amortization (EBITDA) hidden
Ratio
EV/EBITDA hidden
Benchmarks
EV/EBITDA, Competitors
Abbott Laboratories hidden
AbbVie Inc. hidden
Amgen Inc. hidden
Biogen Inc. hidden
Bristol-Myers Squibb Co. hidden
Celgene Corp. hidden
Eli Lilly & Co. hidden
Gilead Sciences Inc. hidden
Johnson & Johnson hidden
Merck & Co. Inc. hidden
Pfizer Inc. hidden
Regeneron Pharmaceuticals Inc. hidden
EV/EBITDA, Sector
Pharmaceuticals & Biotechnology hidden
EV/EBITDA, Industry
Health Care hidden

Based on: 10-K (filing date: 2019-02-15).

If company EV/EBITDA is lower then the EV/EBITDA of benchmark then company is relatively undervalued.

Otherwise, if company EV/EBITDA is higher then the EV/EBITDA of benchmark then company is relatively overvalued.

Enterprise Value to EBITDA Ratio, Historical

Allergan PLC, historical EV/EBITDA calculation, comparison to benchmarks

Microsoft Excel LibreOffice Calc
Dec 31, 2018 Dec 31, 2017 Dec 31, 2016 Dec 31, 2015 Dec 31, 2014
Selected Financial Data (USD $ in thousands)
Enterprise value (EV)1 hidden hidden hidden hidden hidden
Earnings before interest, tax, depreciation and amortization (EBITDA)2 hidden hidden hidden hidden hidden
Ratio
EV/EBITDA3 hidden hidden hidden hidden hidden
Benchmarks
EV/EBITDA, Competitors
Abbott Laboratories hidden hidden hidden hidden hidden
AbbVie Inc. hidden hidden hidden hidden hidden
Amgen Inc. hidden hidden hidden hidden hidden
Biogen Inc. hidden hidden hidden hidden hidden
Bristol-Myers Squibb Co. hidden hidden hidden hidden hidden
Celgene Corp. hidden hidden hidden hidden hidden
Eli Lilly & Co. hidden hidden hidden hidden hidden
Gilead Sciences Inc. hidden hidden hidden hidden hidden
Johnson & Johnson hidden hidden hidden hidden hidden
Merck & Co. Inc. hidden hidden hidden hidden hidden
Pfizer Inc. hidden hidden hidden hidden hidden
Regeneron Pharmaceuticals Inc. hidden hidden hidden hidden hidden
EV/EBITDA, Sector
Pharmaceuticals & Biotechnology hidden hidden hidden hidden hidden
EV/EBITDA, Industry
Health Care hidden hidden hidden hidden hidden

Based on: 10-K (filing date: 2019-02-15), 10-K (filing date: 2018-02-16), 10-K (filing date: 2017-02-24), 10-K (filing date: 2016-02-26), 10-K (filing date: 2015-02-18).

1 See Details »

2 See Details »

2018 Calculations

3 EV/EBITDA = EV ÷ EBITDA
= hidden ÷ hidden = hidden

Ratio Description The company
EV/EBITDA EV/EBITDA is a valuation indicator for the overall company rather than common stock. Allergan PLC’s EV/EBITDA ratio declined from 2016 to 2017 but then increased from 2017 to 2018 exceeding 2016 level.